Home News Insights Trading halts Paper trading Guide Community My account

Market calendarNext market opening

Display in USD

Loading news article.

U.S. stock guide
Scanner guide
Paper trading guide
Terms of service
Privacy policy
Announcements
FAQ

Support: help@wapeb.comPartnerships: partnership@wapeb.com

WAPE is a free research, analysis and paper trading service. It does not place real securities orders. Market data and AI summaries are for information only, not investment advice or stock recommendations. Information may include delays, errors or estimates. Check original sources and supporting materials. You are responsible for your investment decisions and any resulting gains or losses.

Language한국어 English

Loading news article.

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026 | WAPE

Back All news

NewsPR Newswire

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026

Oct 29, 2026, 11:30 ET · Published

View source

Article summary

Presentation will highlight how findings from the PARADIGM program are informing the clinical development strategy for PARAGON CAMBRIDGE, Mass., Oct. 29, 2026 — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense" or the "Company"), a biotechnology company developing...

An excerpt from the original article.

Related companies

NeuroSense Therapeutics Ltd. Ordinary SharesNRSNView stock

NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026

Article summary

Related companies

Analyzed by WAPE AI.

Comments —